Miami, Fla. (April 5, 2017) – Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, and Syapse, a market leader in precision oncology solutions, today announced that they will team up to launch a new precision medicine initiative at Sylvester to help make personalized cancer care in South Florida and throughout the Southeastern U.S. more effective. By partnering with Syapse, Sylvester physicians will be able to more efficiently deliver personalized care that matches patients with targeted, cutting-edge therapies based on the clinical and molecular profile of the patient, leading to improved survival rates and better health outcomes.
“We are excited about this partnership with Syapse because it will help us ensure that our cancer patients receive the best precision care,” said Jonathan C. Trent, M.D., Ph.D., associate director of clinical research at Sylvester and professor of medicine at the University of Miami Miller School of Medicine. “Matching a cancer patient with a certain treatment based on the cancer’s molecular profile is among the most promising treatment options in this age of personalized medicine.”
Through the partnership with Syapse, Sylvester physicians will now have a robust platform that brings together clinical, molecular, treatment, and outcomes data to power this new era of precision medicine clinical workflows. The Syapse platform will provide access to the largest, real-world precision oncology data sharing consortium in the world, enabling oncologists to make better decisions for their patients using real-world treatment and outcomes data on clinically and molecularly similar patients.
“Our new partnership with Sylvester will give physicians the tools they need to deliver cutting-edge treatments to cancer patients in South Florida,” said Syapse CEO Ken Tarkoff. “Democratizing access to precision medicine is key to advancing the state of cancer care throughout the country. We’re excited to work with Sylvester and their network of satellite locations to ensure all cancer patients have access to targeted, effective treatment.”
“No other cancer center or hospital in South Florida offers the breadth of personalized treatment options as Sylvester,” said Trent. “At Sylvester, we understand that each patient is unique, that each cancer is unique, and, consequently, each cancer treatment has to be unique. This partnership with Syapse helps us achieve that goal.”
Sylvester joins a growing number of leading health systems that have adopted the Syapse platform, including Intermountain Healthcare, Providence St. Joseph’s Health, Stanford Healthcare, Henry Ford Health System, Catholic Health Initiatives, Dignity Health, and many more.
Syapse provides hospitals and health systems with a point-of-care software solution, enabling physicians to treat patients with precision medicine. The platform centralizes, organizes, and presents structured clinical and genomic data to providers at the point of care. The robust data infrastructure and provider-facing interface support complex clinical decisions, facilitate new provider workflows, and enable data-driven quality improvement efforts. Syapse enables data sharing across health systems, supporting the nation’s largest precision oncology data-sharing network. Health systems can access real-world treatment and outcomes data on clinically and molecularly similar patients, rapidly advancing the quality of care using real-world evidence.
Syapse is a market leader in precision oncology solutions that helps health systems and providers deliver cutting-edge treatments, resulting in better health outcomes and lower costs. Syapse offers a robust software platform that brings together previously fragmented clinical, molecular, and outcomes data for delivery within a physician's workflow. In addition, Syapse customers have access to the Syapse network, the largest precision oncology data-sharing consortium in the world. Leading health systems, including Intermountain Healthcare, Providence St. Joseph Health, and Stanford Cancer Institute, have adopted Syapse to manage nearly one million active cancer cases across 25 States and in nearly 300 hospitals. The company was founded by Stanford-trained scientists and is backed by Ascension Ventures, Safeguard Scientifics (NYSE:SFE), Social Capital, GE Ventures, Intermountain Healthcare Innovation Fund I, LP. For more information, visit http://syapse.com/ or follow us on Twitter, LinkedIn, or Facebook.
About Sylvester Comprehensive Cancer Center
Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System and the University of Miami Miller School of Medicine, is among the nation’s leading cancer centers and South Florida's only Cancer Center of Excellence. A 2015 study by Memorial Sloan Kettering Cancer Center, published in The Journal of the American Medical Association, showed that cancer patients treated at Sylvester have a 10 percent higher chance of survival than those treated at nearly any other cancer center in the nation. With the combined strength of more than 120 cancer researchers and 130 cancer specialists, Sylvester discovers, develops and delivers more targeted therapies, providing the next generation of cancer clinical care – precision cancer medicine – to each patient. Our comprehensive diagnostics, coupled with teams of scientific and clinical experts who specialize in just one type of cancer, enable us to better understand each patient’s individual cancer and develop treatments that target the cells and genes driving the cancer's growth and survival, leading to better outcomes. At Sylvester, patients have access to more treatment options and more cancer clinical trials than most hospitals in the southeastern United States. To better serve current and future patients, Sylvester has a network of conveniently located outpatient treatment facilities in Miami, Kendall, Hollywood, Plantation, Deerfield Beach, Coral Springs, and Coral Gables. For more information, visit sylvester.org.